Eyenovia, Inc. (EYEN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol EYEN
- Company Eyenovia, Inc.
- Price $15.82
- Changes Percentage 49.81
- Change 5.26
- Day Low $10.7
- Day High $17.09
- Year High $124.8
- Year Low $0.85
- Market Cap $80,750,975
- Price Avg 50 EMA (D) $4.53
- Price Avg 200 EMA (D) $9.74
- Exchange NASDAQ
- Volume 4,562,234
- Average Volume 4,652,726
- Open $10.7
- Previous Close $10.56
- EPS -42.65
- PE -0.37
- Earnings Announcement 2025-08-11 10:59:00
- Shares Outstanding $5,104,360
Company brief: EYENOVIA, INC. (EYEN )
- Healthcare
- Biotechnology
- Mr. Michael M. Rowe
- https://www.eyenovia.com
- US
- N/A
- 01-25-2018
- US30234E1047
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.